Literature DB >> 32410219

PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders.

Shusuke Tomoshige1, Minoru Ishikawa1.   

Abstract

Neurodegenerative disorders (NDs) are a group of diseases that cause neural cell damage, leading to motility and/or cognitive dysfunctions. One of the causative agents is misfolded protein aggregates, which are considered as undruggable in terms of conventional tools, such as inhibitors and agonists/antagonists. Indeed, there is currently no FDA-approved drug for the causal treatment of NDs. However, emerging technologies for chemical protein degradation are opening up the possibility of selective elimination of target proteins through physiological protein degradation machineries, which do not depend on the functions of the target proteins. Here, we review recent efforts towards the treatment of NDs using chemical protein degradation technologies, and we briefly discuss the challenges and prospects.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  PROTACs; autophagy inducers; drug discovery; neurodegenerative disorders; protein degradation

Year:  2020        PMID: 32410219     DOI: 10.1002/anie.202004746

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  9 in total

1.  Conversion of a PROTAC Mutant Huntingtin Degrader into Small-Molecule Hydrophobic Tags Focusing on Drug-like Properties.

Authors:  Keigo Hirai; Hiroko Yamashita; Shusuke Tomoshige; Yugo Mishima; Tatsuya Niwa; Kenji Ohgane; Mayumi Ishii; Kayoko Kanamitsu; Yui Ikemi; Shinsaku Nakagawa; Hideki Taguchi; Shinichi Sato; Yuichi Hashimoto; Minoru Ishikawa
Journal:  ACS Med Chem Lett       Date:  2022-02-16       Impact factor: 4.345

Review 2.  Aptamer-Based Cancer Cell Analysis and Treatment.

Authors:  Limei Wu; Yutong Zhang; Zhimin Wang; Yue Zhang; Jianmei Zou; Liping Qiu
Journal:  ChemistryOpen       Date:  2022-10       Impact factor: 2.630

3.  Protein Degradation Inducers of Androgen Receptor by Conjugation of Antagonists Androgen Receptor and E3 Ligase Ligand.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-09-17       Impact factor: 4.632

4.  Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.

Authors:  Xiao Zhang; Huiying Liu; Jia He; Chong Ou; Thomas C Donahue; Musleh M Muthana; Lishan Su; Lai-Xi Wang
Journal:  ACS Chem Biol       Date:  2022-03-22       Impact factor: 4.634

5.  A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions.

Authors:  Le Guo; Yaxian Zhou; Xueqing Nie; Zhongrui Zhang; Zhen Zhang; Chunrong Li; Taobo Wang; Weiping Tang
Journal:  Eur J Med Chem       Date:  2022-04-01       Impact factor: 7.088

6.  Is PROTAC technology really a game changer for central nervous system drug discovery?

Authors:  Kayla Farrell; Timothy J Jarome
Journal:  Expert Opin Drug Discov       Date:  2021-04-19       Impact factor: 7.050

Review 7.  Key Considerations in Targeted Protein Degradation Drug Discovery and Development.

Authors:  Liena Qin; Han Dai; Junfeng Wang
Journal:  Front Chem       Date:  2022-08-01       Impact factor: 5.545

Review 8.  Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.

Authors:  Gunjan Thakur; Vikas Kumar; Keun Woo Lee; Chungkil Won
Journal:  Genes (Basel)       Date:  2022-08-11       Impact factor: 4.141

9.  Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.

Authors:  Guoshun Luo; Zhenbang Li; Xin Lin; Xinyu Li; Yu Chen; Kun Xi; Maoxu Xiao; Hanlin Wei; Lizhe Zhu; Hua Xiang
Journal:  Acta Pharm Sin B       Date:  2020-11-06       Impact factor: 11.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.